Drug Combination Details
| General Information of the Combination (ID: C89866) | |||||
|---|---|---|---|---|---|
| Name | Gossypol NP Info | + | BRD4770 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Increase | Autophagosome formation | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| HPAC | CVCL_3517 | Pancreatic adenocarcinoma | Homo sapiens | |||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. Cell Death Dis. 2013 Jun 27;4(6):e690. | |||
